scholarly journals The single nucleotide polymorphisms rs11761556 and rs12706832 of the leptin gene are associated with type 2 diabetes mellitus in the iraqi population

2021 ◽  
pp. 5-5
Author(s):  
Karar Musafer ◽  
Fahrul Huyop ◽  
Mufeed Ewadh ◽  
Eko Supriyanto ◽  
Tahreer Al-Thuwaini ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Single Strand Conformation Polymorphism ◽  
Model Assessment ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide

This study was conducted to assess the potential association between leptin (LEP) gene polymorphisms and type 2 diabetes mellitus (T2DM) in Iraqi patients. Genomic DNA was extracted from 120 diabetic subjects and 100 controls. Three specific PCR fragments were designed to flank three highly frequent single nucleotide polymorphism (SNP)s within LEP, rs11761556, rs12706832 and rs2167270. The amplified loci were genotyped by PCR-single-strand conformation polymorphism (SSCP) followed by Sanger sequencing for representative genotypes. Logistic regression analysis was performed to detect the association between the targeted genetic variants and T2DM. PCR-SSCP genotyping showed three banding patterns for all three targeted SNPs. Individuals with the AA genotype in both rs11761556 and rs12706832 SNPs showed significantly higher (P<0.05) body mass index (BMI), waist circumference (WC), fasting blood glucose (FBG), hemoglobin A1c (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), insulin, low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) values than those with other genotypes. Association analysis revealed that individuals with the A allele exhibited a greater risk of T2DM. Data of the present investigation indicated that both rs11761556 and rs12706832 SNPs exerted a noticeable association with T2DM. The study suggests implementing both rs11761556 and rs12706832 SNPs in the early detection of T2DM.

scholarly journals Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus

2014 ◽  
Vol 37 (4) ◽  
pp. 243 ◽  
Author(s):  
Masahiro Ohira ◽  
Takashi Yamaguchi ◽  
Atsuhito Saiki ◽  
Noriko Ban ◽  
Hidetoshi Kawana ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Hypoglycemic Agents ◽  
Low Density

Purpose: Type 2 diabetes is known to be associated with increasing cardiovascular mortality. Malondialdehyde-modified LDL (MDA-LDL) is an oxidized LDL and is increased in patients with diabetes or hypertriglyceridemia. Elevated MDA-LDL has been reported to be a risk factor of atherosclerosis or cardiovascular disease. Sitagliptin is a dipeptidyl peptidase-4 inhibitor and a new class of hypoglycemic agents. In this study, the effects of increasing the dose of metformin and add-on sitagliptin on MDA-LDL were examined in type 2 diabetes patients. Methods: Seventy patients with type 2 diabetes, inadequately controlled despite on-going treatment with metformin 500 mg/day, were enrolled in this randomized controlled trial. The patients received additional metformin (500 mg/day) or sitagliptin (50 mg/day) for 6 months, and changes in metabolic parameters including MDA-LDL were evaluated. Results: After 6 months of treatment, add-on sitagliptin (n=35) improved fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) to significantly greater extent than increasing the dose of metformin (n=35). There were no differences in total cholesterol and low-density lipoprotein cholesterol levels between two groups. MDA-LDL levels (mean±S.E.) decreased significantly with increasing the dose of metformin (from 94.40±6.35 to 77.83±4.74 U/L, P < 0.005), but remained unchanged with add-on sitagliptin treatment (from 89.94±5.59 to 98.46±6.78 U/L, p > 0.05). Multiple linear regression analysis identified increasing the dose of metformin treatment as the only independent factor associated with decreased MDA-LDL (β coefficient 0.367, P < 0.0119), and no significant correlation between change in MDA-LDL and fasting blood glucose or HbA1c. Conclusion: These results suggest that increasing the dose of metformin improves serum MDA-LDL levels in type 2 diabetes mellitus.

scholarly journals Association Between Pulse Index and Metabolic syndrome in Individuals with Type 2 Diabetes Mellitus: Outcome of a Twelve-Weeks Therapeutic Exercise

2009 ◽  
pp. 10-15
Author(s):  
Ade Fatai Adeniyi ◽  
Arinola O Sanya ◽  
A A Fasanmade ◽  
B Tijjani ◽  
A E Uloko
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Cardiovascular Fitness ◽  
Therapeutic Exercises

Background and Objective: Metabolic syndrome (MS) is an entity with clustering of cardiovascular risk factors and is associated with Type 2 Diabetes Mellitus (T2DM). Low level cardiovascular fitness is also associated with risk of T2DM. An association between Pulse Index (PI) and MS requires further description. This study sought to determine the association between PI and components of MS. Methods: Seventy-seven participants/subjects aged 48.6±6.52 years with T2DM were enrolled into the study at Aminu-Kano Teaching Hospital, Kano, Nigeria. PI and components of MS including Fasting Blood Glucose (FBG), Glycosylated Haemoglobin (HBAlc), High-Density Lipoprotein (HDL-CHOL), Triglycerides (TRIG.), Blood Pressure (BP) and obesity were assessed before and after twelve-week therapeutic exercises. Results: Inverse correlations were obtained for PI and each ofFBG (r=-0.45), HBAlc (r=-0.52), TRIG (r=-0.26), BP(r=-0.43/-0.32), Waist Circumference (r=-0.53), BMI (r=-0.79), blood pressure (r=-0.43/-0.32) except HDL-CHOL (r= 0.67), (P< 0.05 for all the subjects/participants). Conclusions: Low-levels of PI were associated with poor glycaemia, hypertension, obesity and dyslipidaemia. Therapeutic exercises aimed at improving cardiovascular fitness may have significant improvement on MS. which in turn aids the prevention of both T2DM and cardiovascular diseases. Keywords: Type 2 Diabetes Mellitus, Cardiovascular fitness, aerobic exercises, Pulse Index'

Coagulopathy in Type 2 Diabetes Mellitus: Pathological Mechanisms and the Role of Factor XIII-A Single Nucleotide Polymorphisms

2019 ◽  
Vol 15 (6) ◽  
pp. 446-455
Author(s):  
Marry-ann Ntanyane Phasha ◽  
Prashilla Soma ◽  
Etheresia Pretorius ◽  
Alia Phulukdaree
Keyword(s):  
Oxidative Stress ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Single Nucleotide Polymorphisms ◽  
Factor Xiii ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Underlying Mechanisms

The prevalence of type 2 diabetes mellitus (T2DM) has quadrupled within three decades since 1980, affecting 422 million adults in 2016. It remains one of the most common noncommunicable chronic diseases and the underlying risk factor for cardiovascular diseases worldwide. There are different underlying mechanisms that play a role in the development of pathologies associated with the disease such as hyperglycaemia, oxidative stress, obesity, inflammation and hypercoagulation; each of which are interlinked. Hyperglycaemia, oxidative stress and obesity play a huge role in the activation of inflammation and coagulation. Activation of inflammatory pathways increases the production of thrombin which predisposes the development of thrombotic related diseases. One of the factors that contribute to the increase of thrombin is the impairment of the fibrinolysis process due to decreased expression of tissue-plasminogen activator (tPA) by increased levels of plasminogen activator inhibitor-1 (PAI-1). Coagulation factor XIII (FXIII), a transglutaminase that is composed of subunits A and B (FXIII-A2B2), is essential for the last step of fibrin clot formation in the coagulation pathway. Genetic variation of FXIII-A in the form of single nucleotide polymorphisms (SNPs) alters the activity of FXIII, altering clot properties which influence disease outcomes. This review discusses the link between underlying mechanisms of T2DM, well known FXIII-A variants and coagulation.

Sign in / Sign up

Export Citation Format

Share Document